Viking Therapeutics Surges on Positive GLP-1 Maintenance Dosing Data
Viking Therapeutics (NASDAQ:VKTX) surged by 26.5% following the release of positive topline data from a maintenance dosing study for its lead drug candidate, VK2735, which showed efficacy with monthly and every-other-week administration schedules. The results address adherence issues common in injectable GLP-1 therapies used for obesity treatment. Despite Viking's strong performance, other companies in the obesity sector remained largely unaffected; Structure Therapeutics (NASDAQ:GPCR) declined slightly while Eli Lilly (NYSE:LLY) gained 1% and Novo Nordisk (NYSE:NVO) fell. Traders viewed the news as a company-specific development rather than an industry-wide catalyst. With $502 million in cash reserves and two Phase 3 trials fully enrolled, Viking is positioned to maintain control over its timeline without immediate pressure for acquisition.
Tickers: $GPCR $LLY $NVO $VKTX